Core Viewpoint - The stock of Baiaosaitu-B (02315) surged over 11% during trading, reaching a new historical high of 44 HKD, and is currently up 7.29% at 42.38 HKD with a trading volume of 81.9068 million HKD [1] Group 1: Agreement Details - On January 9, Baiaosaitu announced a licensing agreement with Yushibo to systematically evaluate the BsADC projects through a structured assessment mechanism [1] - The agreement grants Yushibo an option for global exclusive licensing of two BsADC projects from Baiaosaitu [1] - Baiaosaitu is entitled to receive an upfront payment for the option, and upon Yushibo exercising the option, Baiaosaitu will receive additional payments including option exercise fees, development and regulatory milestone payments, commercialization milestone payments, and sales royalties [1]

Core Viewpoint - Yiming Anke-B (01541) has seen a significant stock price increase following the approval from the National Medical Products Administration of China for clinical trials of IMM01 (Tadapaxip) for atherosclerosis treatment [1] Group 1: Company Developments - Yiming Anke has received approval for clinical trials of IMM01 (Tadapaxip) for treating atherosclerosis, holding global intellectual property and commercialization rights for this drug [1] - The company possesses a patent family for IMM01, with authorized patents in China, the United States, Japan, and the European Union [1] Group 2: Market Analysis - Guoyuan International's report indicates that the company has regained global rights for IMM2510 and IMM27M, which will accelerate the pace of global development [1] - Clinical data for IMM2510 is reported to be excellent, with good safety and significant differentiation advantages [1] - The company is recognized as a global innovator in CD47 fusion proteins, with a rich pipeline and promising applications in oncology, autoimmune diseases, and cardiovascular fields [1] - The current market capitalization is only 2.7 billion HKD, indicating a significant undervaluation, and the company is recommended for active monitoring [1]

Core Viewpoint - The company Yiming Anke-B (01541) has received approval from the National Medical Products Administration of China for clinical trials of IMM01 (Tida-paisip) for the treatment of atherosclerosis, which has positively impacted its stock price [1] Group 1: Company Developments - Yiming Anke-B's stock price rose over 10% in early trading, currently up 8.63% at HKD 6.67, with a trading volume of HKD 11.1965 million [1] - The company holds global intellectual property and commercialization rights for IMM01 (Tida-paisip) and has a patent family that includes authorized patents in China, the United States, Japan, and the European Union [1] Group 2: Research and Development Insights - Guoyuan International reported that the company has regained global rights for IMM2510 and IMM27M, which will accelerate the pace of global development [1] - Clinical data for IMM2510 is reported to be excellent with good safety and significant differentiation advantages [1] - The company’s R&D pipeline is expanding, enhancing its risk resistance, with promising clinical efficacy data for the CD47CD20 dual antibody (IMM0306), which is expected to become a major drug in the autoimmune field [1] Group 3: Market Valuation - The company is recognized as a global innovator in CD47 fusion proteins, with a rich pipeline and broad application prospects in oncology, autoimmune diseases, and cardiovascular fields [1] - Currently, the market capitalization is only HKD 2.7 billion, indicating a significant undervaluation, and it is recommended to pay close attention to the company [1]

Core Viewpoint - Beam Therapeutics' stock price surged over 20% following the announcement of its commitment to developing sustainable and predictable models for advancing precision gene drug development [1] Group 1: Financial Performance - The company's stock closed at $33.69, reflecting a 22.29% increase [1] - As of the end of 2025, the company holds cash, cash equivalents, and marketable securities valued at approximately $1.25 billion [1] - The expected operational funding support period has been extended to 2029, providing strong backing for the anticipated launch of risto-cel and the execution of the BEAM-302 key development plan [1] Group 2: Strategic Focus - The company highlighted recent progress in its liver-targeted gene disease and hematology franchise projects [1] - The strategic focus for 2026 was outlined, emphasizing the ongoing expansion of its liver-targeted gene disease franchise [1]

Core Viewpoint - The commercial aerospace sector, represented by low-orbit satellites, experienced a significant pullback, while the Hong Kong medical sector showed strong gains, indicating a potential shift in market momentum [1] Group 1: Market Performance - The Hong Kong medical ETF, Huabao (159137), surged over 5%, leading the market in real-time ETF gains, with an intraday increase of over 8% [1] - Since 2026, the Hong Kong medical theme index has risen over 20%, highlighting the recent popularity of "Hong Kong medical" stocks [1] - In 2025, the annual increase of the Hong Kong medical theme index reached 48.20% [1] Group 2: Historical Context - The Hong Kong medical sector has undergone four years of adjustment, with the theme index currently at a historically low point in terms of valuation [1] - As of the end of 2025, the index level has retreated over 65% from its historical peak in 2021, with a TTM price-to-earnings ratio of 29.43, which is below 65% of the historical range since the base date [1] Group 3: Investment Opportunities - The Hong Kong medical ETF, Huabao (159137), tracks the CSI Hong Kong medical theme index, covering four major sectors: CXO, medical commerce and services, medical devices, and biopharmaceuticals [1] - Over 80% of the ETF's weight is concentrated in leading companies within CXO, internet healthcare, and high-end medical devices, with over 85% of the constituents being "Hong Kong exclusive" stocks, including unique offerings like JD Health and Alibaba Health [1]

每经AI快讯，1月12日夜间，智飞生物发布2025年度业绩预告显示，公司预计2025年归属于上市公司股 东的净利润亏损106.98亿元~137.26亿元，上年同期盈利20.18亿元。 每日经济新闻 ...

Group 1 - The core viewpoint of the article highlights the significant rise in the stock price of Fuhong Hanlin (02696), which increased by 8.05% to HKD 69.80, with a trading volume of HKD 22.8793 million [2][5] - On January 9, Fuhong Hanlin presented its Phase II proof-of-concept data for PD-L1 ADC HLX43 targeting recurrent/metastatic esophageal squamous cell carcinoma (ESCC) at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) [5] - The data released indicates promising efficacy and good safety profile of HLX43 in previously treated advanced ESCC patients, demonstrating its potential as a treatment option [5] Group 2 - HLX43 has shown consistent efficacy and safety trends across multiple solid tumor indications, including non-small cell lung cancer, cervical cancer, esophageal squamous cell carcinoma, and thymic cancer [5] - The broad anti-tumor potential of HLX43 is gradually being validated through clinical practice, laying a crucial foundation for the expansion into more indications [5]

消息面上，1月11日，博安生物发布公告，公司董事会欣然宣布，其自主研发的地舒单抗注射液(60mg) (代号BA6101)已获玻利维亚国家药品和卫生技术局(AGEMED)批准上市。BA6101为原研参照药Prolia的 生物类似药，在全球范围内Prolia广泛应用于骨质疏松症的治疗。BA6101的适应症与原研参照药相同。 BA6101基于本公司全球研发策略开发，并计划在全球多个国家及地区开展商业化。当前，BA6101在英 国的上市许可申请正处于审批阶段，本公司计划在欧洲、美国、日本等国家和地区提交上市许可申请。 智通财经APP获悉，博安生物(06955)涨超6%，截至发稿，涨6.28%，报9.98港元，成交额4988.45万港 元。 ...

博安生物(06955)涨超6%，截至发稿，涨6.28%，报9.98港元，成交额4988.45万港元。 消息面上，1月11日，博安生物发布公告，公司董事会欣然宣布，其自主研发的地舒单抗注射液(60mg) (代号BA6101)已获玻利维亚国家药品和卫生技术局(AGEMED)批准上市。BA6101为原研参照药Prolia的 生物类似药，在全球范围内Prolia广泛应用于骨质疏松症的治疗。BA6101的适应症与原研参照药相同。 BA6101基于本公司全球研发策略开发，并计划在全球多个国家及地区开展商业化。当前，BA6101在英 国的上市许可申请正处于审批阶段，本公司计划在欧洲、美国、日本等国家和地区提交上市许可申请。 ...

Core Viewpoint - Vaccine manufacturer Moderna expects sales of approximately $1.9 billion for the previous year, nearing the upper limit of its prior forecast of $1.6 billion to $2 billion, but significantly lower than revenue levels during the pandemic [1] Financial Performance - The company has reduced its 2025 operating expense forecast by $200 million, adjusting the range to $5 billion to $5.2 billion [1] - Moderna anticipates an ending cash balance of $8.1 billion, exceeding the previous forecast of $6.5 billion to $7 billion [1] Future Outlook - The company reaffirms its goal of achieving revenue growth of up to 10% this year [1] - Moderna expects to receive regulatory approval for an independent flu vaccine and a combined flu vaccine this year [1]